Lessons on chemical classes

In July this year, Wragge & Co's IP team reported on the German Appeal Court decision on Eli Lilly's patent for the anti-psychotic drug olanzapine. The German court granted an injunction despite the Federal Patent Court having revoked the patent in suit a year earlier for lack of novelty. 

The validity of the EP(UK) patent on olanzapine has now also been considered by the UK High Court. On 13 October 2008 the UK High Court held the patent to be valid. This decision is interesting as it analyses the UK law on "selection patents" and continues an emerging UK trend of following European Patent Office jurisprudence. 

Read Wragge & Co IP team's expert analysis on this subject for a more in-depth look at the issues.